Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-19T10:31:10.187Z Has data issue: false hasContentIssue false

18 - Follicular lymphomas

Published online by Cambridge University Press:  10 January 2011

By
Francisco J. Hernandez-Ilizaliturri  and
Myron S. Czuczman
Edited by
Susan O'Brien ,
Julie M. Vose  and
Hagop M. Kantarjian
Francisco J. Hernandez-Ilizaliturri
Affiliation:
Departments of Medicine and Immunology, Roswell Park Institute, Buffalo, NY, USA
Myron S. Czuczman
Affiliation:
Departments of Medicine and Immunology, Roswell Park Institute, Buffalo, NY, USA
Susan O'Brien
Affiliation:
University of Texas/MD Anderson Cancer Center, Houston
Julie M. Vose
Affiliation:
University of Nebraska Medical Center, Omaha
Hagop M. Kantarjian
Affiliation:
University of Texas/MD Anderson Cancer Center, Houston
Get access

Summary

Introduction

Follicular lymphoma (FL) is the most common type of indolent B-cell lymphoma diagnosed in the United States. A better understanding of the biology of disease and the development of novel targeted agents are challenging prior dogmatic concepts regarding the standard therapeutic approach to FL.

In recent years, the lymphoma field has seen significant progress with respect to the identification of clinical, tumor-associated, and host-associated prognostic factors, as well as the development of novel functional imaging (e.g., positron emission tomography [PET] scans). Improvements in molecular diagnostics allow a clearer distinction between various lymphoma subtypes. Perhaps the single most important advance has been the development and integration of monoclonal antibodies (mAbs) into the treatment of B-cell lymphoma which has resulted in a steady improvement in progression-free survival (PFS) and overall survival (OS) of patients. This chapter summarizes the advances achieved in the last two decades that have led to the current approach and management of patients with FL.

Pathogenesis of FL

As technology and its applications have improved over the last two decades, there has been a parallel improvement in our understanding of the molecular mechanisms responsible not only for the development of FL, but also to explain its clinical heterogeneity. Ontologically, FL arises from germinal B cells usually as a result of deregulation in the apoptotic machinery. FL was one of the first lymphomas in which a molecular defect was defined.

Type
Chapter
Information
Management of Hematologic Malignancies , pp. 338 - 366
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bende, RJ, Smit, , Noesel, CJ. Molecular pathways in follicular lymphoma. Leukemia 2007;21:18–29.CrossRefGoogle ScholarPubMed
Tsujimoto, Y, Finger, LR, Yunis, J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1994;226:1097–9.CrossRefGoogle Scholar
Cleary, ML, Sklar, J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A 1985;82:7439–43.CrossRefGoogle Scholar
Bakhshi, A, Jensen, JP, Goldman, P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985;41:899–906.CrossRefGoogle Scholar
Meijerink, JPP. t(14:18): a journey to eternity. Leukemia 1997;11:2175–87.CrossRefGoogle Scholar
Ross, CW, Ouillette, PD, et al. Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res 2007;13:4777–85.CrossRefGoogle ScholarPubMed
Danial, NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 2007; 13:7254–63.CrossRefGoogle ScholarPubMed
Zha, H, Raffeld, M, Charboneau, L, et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest 2004;84:235–44.CrossRefGoogle ScholarPubMed
Schraders, M, Jong, D, Kluin, P, et al. Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. J Pathol 2005; 205:329–35.CrossRefGoogle ScholarPubMed
McDonnell, TJ, Deane, N, Platt, FM, et al. BCL2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79–88.CrossRefGoogle Scholar
Strasser, A, Harris, AW, Bath, ML, et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and BCL2. Nature 1990;348:331–3.CrossRefGoogle Scholar
Horsman, , Connors, JM, Pantzar, T, et al. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 2001;30:375–82.CrossRefGoogle Scholar
Yunis, JJ, Frizzera, G, Oken, MM, et al. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med 1987;316:79–84.CrossRefGoogle ScholarPubMed
Speaks, SL, Sanger, WG, Linder, J, et al. Chromosomal abnormalities in indolent lymphoma. Cancer Genet Cytogenet 1987;27:335–44.CrossRefGoogle ScholarPubMed
Höglund, M, Sehn, L, Connors, JM, et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 2004; 39:195–204.CrossRefGoogle ScholarPubMed
Alizadeh, AA, Eisen, MB, Davis, RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503–11.CrossRefGoogle ScholarPubMed
Davis, RE, Brown, KD, Siebenlist, U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. Exp Med 2001; 194:1861–74.CrossRefGoogle ScholarPubMed
Jong, D, Rosenwald, A, Chhanabhai, M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications–a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805–12.CrossRefGoogle ScholarPubMed
Dave, SS, Wright, G, Tan, B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159–69.CrossRefGoogle ScholarPubMed
Bohen, SP, Troyanskaya, OG, Alter, O, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A 2003;100:1926–30.CrossRefGoogle ScholarPubMed
Glas, AM, Kersten, MJ, Delahaye, LJ, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005;105:301–7.CrossRefGoogle ScholarPubMed
Jong, D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005;23:6358–63.CrossRefGoogle ScholarPubMed
Hermans, J, Krol, AD, Groningen, K, et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995;86:1460–3.Google ScholarPubMed
López-Guillermo, A, Montserrat, E, Bosch, F, et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994;12:1343–8.CrossRefGoogle ScholarPubMed
Solal-Céligny, P, Roy, P, Colombat, P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–65.CrossRefGoogle ScholarPubMed
Buske, C, Hoster, E, Dreyling, M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006;108:1504–8.CrossRefGoogle ScholarPubMed
Winter, JN, Gascoyne, RD, Besien, K. Low-grade lymphoma. Hematology Am Soc Hematol Educ Program 2004;203–20.
Hans, CP, Weisenburger, DD, Vose, JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003;101:2363–7.CrossRefGoogle Scholar
Ganti, AK, Weisenburger, DD, Smith, LM, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 2006;17:920–7.CrossRefGoogle ScholarPubMed
Harjunpää, A, Taskinen, M, Nykter, M, et al. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol 2006;135:33–42.CrossRefGoogle Scholar
Glas, AM, Knoops, L, Delahaye, L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390–8.CrossRefGoogle ScholarPubMed
Cerhan, JR, Wang, S, Maurer, MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007;109:5439–46.CrossRefGoogle ScholarPubMed
Farinha, P, Masoudi, H, Skinnider, BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169–74.CrossRefGoogle Scholar
Canioni, D, Salles, G, Mounier, N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008;26:440–6.CrossRefGoogle ScholarPubMed
Taskinen, M, Karjalainen-Lindsberg, ML, Nyman, H, et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007;13:5784–9.CrossRefGoogle ScholarPubMed
Kelley, T, Beck, R, Absi, A, et al. Biologic predictors in follicular lymphoma: importance of markers of immune response. Leuk Lymphoma 2007; 48:2403–11.CrossRefGoogle ScholarPubMed
Taskinen, M, Karjalainen-Lindsberg, ML, Leppä, S. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood 2008;111:4664–7.CrossRefGoogle Scholar
Brice, P, Bastion, Y, Lepage, E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997;15:1110–17.CrossRefGoogle ScholarPubMed
Ardeshna, KM, Smith, P, Norton, A, et al. British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516–22.CrossRefGoogle ScholarPubMed
Wilder, RB, Jones, D, Tucker, SL, et al. Long-term results with radiotherapy for stage I–II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001;51:1219–27.CrossRefGoogle ScholarPubMed
Tsang, RW, Gospodarowicz, MK. Radiation therapy for localized low-grade non-Hodgkin's lymphomas. Hematol Oncol 2005;23:10–17.CrossRefGoogle ScholarPubMed
Horning, SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75–88.Google ScholarPubMed
Young, RC, Longo, DL, Glatstein, E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988;25:11–16.Google ScholarPubMed
Ganti, AK, Bociek, RG, Bierman, PJ, et al. Follicular lymphoma: expanding therapeutic options. Oncology (Williston Park) 2005;19:213–28; discussion 228, 233–6, 239.Google ScholarPubMed
Peterson, BA, Petroni, GR, Frizzera, G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 2003;21:5–15.CrossRefGoogle ScholarPubMed
Ghielmini, M, Rufibach, K, Salles, G, et al. Factors prognostic for response and event free survival and treatment related toxicity in 306 patients with follicular or mantle cell lymphoma randomized to single agent rituximab given at the standard or at a prolonged schedule. Ann Oncol 2005;16:1675–82.CrossRefGoogle Scholar
Czuczman, M, Grillo-Lopez, A, Alkuzweny, B, et al. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leuk Lymphoma 2006; 47:1830–40.CrossRefGoogle Scholar
Solal-Celigny, P, Salles, GA, Brousse, N, et al. Single 4-dose rituximab treatment for low-tumor burden follicular lymphoma (FL): survival analyses with a follow-up (F/Up) of at least 5 years. Blood 2004;104:169a.Google Scholar
Gokhale, AS, Mayadev, J, Pohlman, B, et al. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys 2005;63:194–201.CrossRefGoogle ScholarPubMed
Kaminski, MS, Zelenetz, AD, Press, OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918–28.CrossRefGoogle ScholarPubMed
Herberman, RR, Ortaldo, JR, Bonnard, GD.Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature 1979;277:221–3.CrossRefGoogle ScholarPubMed
Basham, TY, Kaminski, MS, Kitamura, K, et al. Synergistic anti-tumor activity with IFN and anti idiotype monoclonal antibody in murine lymphoma. J Immunol 1986;137:3019–24.Google Scholar
Nakamura, K, Kubo, A, Hosokawa, S, et al. Effect of α-interferon on anti-α-fetoprotein-monoclonal antibody targeting of hepatoma. Oncology 1993;50:35–40.CrossRefGoogle ScholarPubMed
Murray, JL, Zukiwski, AA, Mujoo, K, et al. Recombinant α-interferon enhances tumor targeting of an anti-melanoma monoclonal antibody in vivo. J Biol Response Mod 1990;9:556–63.Google Scholar
Yokota, S, Hara, H, Luo, Y, et al. Synergistic potentiation of in vivo anti-tumor activity of anti-human T-leukemia immunotoxins by recombinant α-interferon. Cancer Res 1990;50:32–7.Google Scholar
Hagenbeek, A, Carde, P, Meerwaldt, JH, et al. Maintenance of remission with human recombinant interferon-α 2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1990;16:41–7.CrossRefGoogle Scholar
Solal-Celigny, P, Lepage, E, Brousse, N, et al. Doxorubicin-containing regimen with or without interferon-α 2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998;16:2332–8.CrossRefGoogle ScholarPubMed
Albertsson, PA, Basse, PH, Hokland, M, et al. NK cells and the tumor microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 2003;24:603–9.CrossRefGoogle Scholar
Cooper, MA, Fehniger, TA, Fuchs, A, et al. NK cell and DC interactions. Trends Immunol 2004;25:47–52.CrossRefGoogle ScholarPubMed
Berinstein, N, Levy, R.Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2. J Immunol 1987;139:971–6.Google ScholarPubMed
Berinstein, N, Starnes, CO, Levy, R.Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2. J Immunol 1988;140:2839–45.Google ScholarPubMed
Golay, J, Manganini, M, Facchinetti, V, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003;88:1002–12.Google ScholarPubMed
Friedberg, JW, Neuberg, D, Gribben, JG, et al. Combination immunotherapy with rituximab and interleukin2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002;117:828–34.CrossRefGoogle ScholarPubMed
Berdeja, JG, Hess, A, Ambinder, RF, et al. Lymphokine activated killer cells augment rituximab antibody dependent cellular cytotoxicity in patients with rituximab refractory lymphoma. Blood 2002;100:2264a.Google Scholar
Nadler, LM, Stashenko, P, Hardy, R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980;40:3147–54.Google ScholarPubMed
Miller, RA, Maloney, DG, Warnke, R, et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982;306:517–22.CrossRefGoogle ScholarPubMed
Kohler, G, Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–7.CrossRefGoogle ScholarPubMed
Barinaga, M. From bench top to bedside. Science 1997;278:1036–9.CrossRefGoogle Scholar
Leget, GA, Czuczman, MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548–51.CrossRefGoogle ScholarPubMed
Piro, LD, White, CA, Grillo-Lopez, AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655–61.CrossRefGoogle ScholarPubMed
McLaughlin, P, Grillo-Lopez, AJ, Link, BK, et al. Chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose, 22-day treatment program. J Clin Oncol 1998;16:2825–33.CrossRefGoogle Scholar
Deans, JP, Schieven, GL, Shu, GL, et al. Association of tyrosine and serine kinases with B cell surface antigen CD20. J Immunol 1993;151:4494–504.Google ScholarPubMed
Shan, D, Ledbetter, JA, Press, OW. Apoptosis of malignant human B cell by ligation of CD20 with monoclonal antibodies. Blood 1998;91:1644–52.Google Scholar
Shan, D, Ledbetter, JA, Press, OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B-cells. Cancer Immunol Immunother 2000;48:673–83.CrossRefGoogle ScholarPubMed
Popoff, IJ, Savage, JA, Blake, J, et al. The association between CD20 and Src-family tyrosine kinases requires an additional factor. Mol Immunol 1998; 35:207–14.CrossRefGoogle ScholarPubMed
Taji, H, Kagami, Y, Okada, Y, et al. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998;89:748–56.CrossRefGoogle ScholarPubMed
Holder, M, Grafton, G, MacDonald, I, et al. Engagement of CD20 suppress apoptosis in germinal center B cells. Eur J Immunol25:3160–4.
Mathas, S, Rickers, A, Bommert, K, et al. Anti-CD20 and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000;60:7170–6.Google ScholarPubMed
Hofmeister, JK, Cooney, D, Coggeshall, KM. Clustered CD20 induced apoptosis: Src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells, Mol Dis 2000;26:133–43.CrossRefGoogle ScholarPubMed
Harjunpaa, A, Junnikkala, S, Meri, S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000;51:634–41.CrossRefGoogle ScholarPubMed
Cragg, MS, French, RR, Glennie, MJ. Signaling antibodies in cancer therapy. Curr Opin Immunol 1999;11:541–7.CrossRefGoogle ScholarPubMed
Hernandez-Ilizaliturri, FJ, Jupudy, V, Oflazoglu, E, et al. Neutrophils contribute to the biological anti-tumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency (SCID) mouse model. Clin Cancer Res 2003;9:5866–73.Google Scholar
Clynes, RA, Towers, TL, Presta, LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;4:443–6.CrossRefGoogle Scholar
O'Keefe, TL, Williams, GT, Davies, SL, et al. Mice carrying a CD20 gene disruption. Immunogenetics 1998;48:125–32.CrossRefGoogle ScholarPubMed
Semac, I, Palomba, C, Kulangara, K, et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 2003;63:534–40.Google ScholarPubMed
Polyak, M, Tailor, SH, Deans, JP. Identification of a cytoplasmic region of CD20 required for its distribution to a detergent-insoluble membrane compartment. J Immunol 1998;161: 3242–8.Google Scholar
Alas, S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001;7:709–23.Google Scholar
Di Gaetano, N, Xiao, Y, Erba, E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114:800–9.CrossRefGoogle Scholar
Davis, TA, Grillo-López, AJ, White, CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18(17):3135–43.CrossRefGoogle ScholarPubMed
Colombat, P, Salles, G, Brousse, N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101–6.CrossRefGoogle ScholarPubMed
Hainsworth, JD, Litchy, S, Burris, HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002;20:4261–7.CrossRefGoogle ScholarPubMed
Colombat, P, Brousse, N, Morschhauser, F, et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F/Up) of 7 years. ASH Annual Meeting Abstracts 2006;108:486.Google Scholar
Ghielmini, M, Rufibach, K, Salles, G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005;16:1675–82.CrossRefGoogle Scholar
Berinstein, NL, Grillo-López, AJ, White, CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995–1001.CrossRefGoogle ScholarPubMed
Gordan, LN, Grow, WB, Pusateri, A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005;23:1096–102.CrossRefGoogle ScholarPubMed
Hainsworth, JD, Litchy, S, Shaffer, DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma–a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088–95.CrossRefGoogle ScholarPubMed
Ghielmini, M, Schmitz, SF, Cogliatti, SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416–23.CrossRefGoogle ScholarPubMed
Hochster, HS, Weller, E, Gascoyne, RD, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. ASH Annual Meeting Abstracts 2005;106:349.Google Scholar
Oers, MH, Klasa, R, Marcus, RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–301.CrossRefGoogle ScholarPubMed
Forstpointner, R, Unterhalt, M, Dreyling, M, et al. German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108(13):4003–8.CrossRefGoogle Scholar
Czuczman, MS, Olejniczak, S, Gowda, A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both a global CD20 gene and protein down-regulation regulated at the pre- and post-transcriptional level. Clin Cancer Res 2008;14:1561–70.CrossRefGoogle Scholar
Olejniczak, S, Hernandez-Ilizaliturri, FJ, Clements, JL, et al. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from down-regulation of Bax and Bak. Clin Cancer Res 2008;14:1550–60.CrossRefGoogle Scholar
Czuczman, MS, Weaver, R, Alkuzweny, B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711–16.CrossRefGoogle ScholarPubMed
Czuczman, MS, Koryzna, A, Mohr, A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694–704.CrossRefGoogle ScholarPubMed
Zinzani, PL, Pulsoni, A, Perrotti, A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22:2654–61.CrossRefGoogle ScholarPubMed
Forstpointner, R, Dreyling, M, Repp, R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064–71.CrossRefGoogle ScholarPubMed
Marcus, R, Imrie, K, Belch, A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–23.CrossRefGoogle ScholarPubMed
Hiddemann, W, Kneba, M, Dreyling, M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–32.CrossRefGoogle ScholarPubMed
Herold, M, Haas, A, Srock, S, et al. East German Study Group Hematology and Oncology Study. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986–92.CrossRefGoogle Scholar
Hale, G, Gia, MQ, Tighe, HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35:118–27.CrossRefGoogle Scholar
Ginaldi, L, Martinis, M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cell. Leuk Res 1998;22:185–91.CrossRefGoogle Scholar
Hale, C, Bartholomew, M, Taylor, V, et al. Recognition of CD52 allelic gene products by Campath-1H antibodies. Immunology 1996;88:183–90.CrossRefGoogle ScholarPubMed
Rowan, WC, Hale, G, Tite, JP, et al. Cross-linking of the Campath-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 1995;7:69–77.CrossRefGoogle ScholarPubMed
Rowan, W, Tite, J, Topley, P, et al. Cross-linking of the Campath-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998; 95:427–36.CrossRefGoogle Scholar
Flynn, J, Byrd, JC.Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000;12:574–81.CrossRefGoogle ScholarPubMed
Gilleece, MH, Dexter, TM.Effect of Campath 1-H antibody on human hematopoietic progenitors in vitro. Blood 1993;82:807–12.Google Scholar
Riechmann, L, Clark, MR, Waldmann, H, et al. Reshaping human antibodies for therapy. Nature 1998;332:323–7.CrossRefGoogle Scholar
Bindon, CI, Hale, G, Bruggemann, M, et al. Human monoclonal IgG antibodies differ in complement activation function at the level of C4 as well as C1q. J Exp Med 1988;268;127–52.CrossRefGoogle Scholar
Lim, S, Davey, G, Marcus, R.Differential response in a patient treated with Campath-1H monoclonal antibody for refractory NHL. Lancet 1993;341:432–3.CrossRefGoogle Scholar
Khorana, A, Bunn, P, Mclaughlin, P, et al. A phase II multicenter study of Campath-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma 2001;41:77–87.CrossRefGoogle ScholarPubMed
Lundin, J, Osterborg, A, Brittinger, G, et al. Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of Campath-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998;16:3257–63.CrossRefGoogle Scholar
Tang, SC, Hewitt, K, Reis, MD, et al. Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymphoma 1996;24:93–101.CrossRefGoogle ScholarPubMed
Moreau, T, Coles, A, Wing, M, et al. Transient increase in symptoms associated with multiple sclerosis. Brain 1996;119:225–37.CrossRefGoogle ScholarPubMed
Lundin, J, Kimby, E, Bjorkholm, M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768–73.CrossRefGoogle Scholar
Faderl, S, Thomas, DA, O'Brien, S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413–15.CrossRefGoogle ScholarPubMed
Dorken, B, Moldenhauer, G, Pezzutto, A, et al. HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 1986;136:4470–9.Google Scholar
Tuscano, JM, Riva, A, Toscano, SN, et al. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood 1999;94:1382–92.Google ScholarPubMed
Shih, LB, Lu, HH, Xuan, H, et al. Internalization and intracellular processing of an anti-B cell lymphoma monoclonal antibody, LL2. Int J Cancer 1994;56:538–45.CrossRefGoogle ScholarPubMed
Kreitman, RJ, Hansen, HJ, Jones, AL, et al. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res 1993;53:819–25.Google ScholarPubMed
Vitetta, ES, Stone, M, Amlot, P, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991;51:4052–8.Google ScholarPubMed
Goldenberg, DM, Horowitz, JA, Sharkey, RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphoma with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991;9:548–64.CrossRefGoogle ScholarPubMed
Leonard, JP, Coleman, M, Matthews, JC, et al. Phase I/II trial of epratuzumab in non-Hodgkin's lymphoma. Blood 2002;100:1388a.Google Scholar
Leonard, JP, Coleman, M, Ketas, JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3051–9.CrossRefGoogle Scholar
Leonard, JP, Coleman, M, Matthews, JC, et al. Combination monoclonal antibody therapy for lymphoma: treatment with epratuzumab (anti-CD22) and rituximab (anti-CD20) is well tolerated. Blood 2001;98:3506a.Google Scholar
Emmanouilides, C, Leonard, JP, Schuster, SJ, et al. A multicenter, phase 2 study of combination antibody therapy with epratuzumab plus rituximab in recurring low-grade NHL. Blood 2003;102:233a.Google Scholar
Goldenberg, DM, Horowitz, JA, Sharkey, RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991;9:548–64.CrossRefGoogle ScholarPubMed
Mattes, MJ, Griffiths, GL, Difil, H, et al. Processing of antibody–radioisotope conjugates after binding to the surface of tumor cells. Cancer 1994;73:787–93.3.0.CO;2-5>CrossRefGoogle ScholarPubMed
Vose, JM, Colcher, D, Gobar, L, et al. Phase I/II trial of multiple dose 131 iodine-Mab LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma 2000;38:91–101.Google ScholarPubMed
Juweid, M, Sharkey, RM, Behr, T, et al. Treatment of non Hodgkin's lymphoma with radiolabeled murine, chimeric or humanized LL2 monoclonal antibody. Cancer Res 1995;55:5899–907.Google ScholarPubMed
Juweid, ME, Stadtmauer, E, Hajjar, G, et al. Pharmacokinetics, dosimetry and initial therapeutic results with (I131) and In111-/Y90 labeled humanized LL2 anti CD22 monoclonal antibody in patients with relapsed, refractory NHL. Clin Cancer Res 1999;5:3292–303.Google Scholar
Salvatore, G, Beers, R, Margulies, I, et al. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002;8:996–1002.Google ScholarPubMed
Kreitman, RJ, Wilson, WH, Bergeron, K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy resistant hairy cell leukemia. N Engl J Med 2001;345:241–7.CrossRefGoogle ScholarPubMed
DiJoseph, JF, Dougher, MM, Kalyandrug, LB, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006;12:242–9.CrossRefGoogle Scholar
Hernandez-Ilizaliturri, FJ, Devineni, S, Arora, S, et al. Targeting CD20 and CD22 with rituximab in combination with CMC-544 results in improved anti-tumor activity against non-Hodgkin's lymphoma (NHL) pre-clinical models. ASH Annual Meeting Abstracts 2005;106:1473.Google Scholar
Hursey, M, Newton, DL, Hansen, HJ, et al. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents; a new generation of therapeutics. Leuk Lymphoma 2002;43:953–9.CrossRefGoogle ScholarPubMed
Czuczman, MS, Thall, A, Witzig, TE, et al. A phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory, follicular lymphoma. J Clin Oncol 2005;23(19):4390–8.CrossRefGoogle ScholarPubMed
Leonard, JP, Friedberg, JW, Younes, A, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;18:216–23.CrossRefGoogle ScholarPubMed
Georgakis, GV, Li, Y, Humphreys, R, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005;130:501–10.CrossRefGoogle ScholarPubMed
Snell, V, Clodi, K, Zhao, S, et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 1997;99:618–24.CrossRefGoogle Scholar
Walczak, H, Miller, RE, Ariail, K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157–63.CrossRefGoogle ScholarPubMed
Pitti, RM, Marsters, SA, Ruppert, S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12 687–90.CrossRefGoogle ScholarPubMed
Pukac, L, Kanakaraj, P, Humphreys, R, et al. Mapatumumab, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005;92:1430–41.CrossRefGoogle Scholar
Cretney, E, Shanker, A, Yagita, H, et al. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 2006;84:87–98.CrossRefGoogle ScholarPubMed
Keane, MM, Ettenberg, SA, Nau, MM, et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999;59:734–41.Google ScholarPubMed
Griffith, TS, Lynch, DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998;10:559–63.CrossRefGoogle ScholarPubMed
Younes, A, Vose, JM, Zelenetz, AD, et al. Results of a phase 2 trial of HGSETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL). Blood 2005;106:146a.Google Scholar
Maddipatla, S, Hernandez-Ilizaliturri, FJ, Knight, J, et al. Augmented anti-tumor activity against B-cell lymphoma by a combination of monoclonal antibodies (mAbs) targeting TRAIL-R1 and CD20. Clin Cancer Res 2007;13:4556–64.CrossRefGoogle Scholar
Teeling, JL, French, RR, Cragg, MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793–800.CrossRefGoogle ScholarPubMed
Beum, PV, Lindorfer, MA, Beurskens, F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008;181:822–32.CrossRefGoogle ScholarPubMed
Glennie, MJ, French, RR, Cragg, MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823–37.CrossRefGoogle ScholarPubMed
Hagenbeek, A, Gadeberg, O, Johnson, P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111:5486–95.CrossRefGoogle ScholarPubMed
Coiffier, B, Lepretre, S, Pedersen, LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood 2008;111:1094–100.CrossRefGoogle ScholarPubMed
Czuczman, MS, Grillo-Lopez, AJ, White, CA, et al. The treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody (rituxan, rituximab) and CHOP chemotherapy. J Clin Oncol 1999;17:268–76.CrossRefGoogle ScholarPubMed
Cheson, BD, Horning, SJ, Coiffier, B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:1244–53.CrossRefGoogle Scholar
Salles, GA, Mounier, N, Guibert, S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824–31.CrossRefGoogle ScholarPubMed
Fisher, RI, LeBlanc, M, Press, OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447–52.CrossRefGoogle ScholarPubMed
Liu, Q, Fayad, L, Cabanillas, F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006;24:1582–9.CrossRefGoogle ScholarPubMed
Kaminski, MS, Estes, J, Zasadny, KR, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259–66.Google ScholarPubMed
Vose, JM, Wahl, RL, Saleh, M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316–23.CrossRefGoogle ScholarPubMed
Wiseman, GA, Gordon, LI, Multani, PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336–42.CrossRefGoogle ScholarPubMed
Witzig, TE, White, CA, Wiseman, GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793–803.CrossRefGoogle ScholarPubMed
Witzig, TE, Gordon, LI, Cabanillas, F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453–63.CrossRefGoogle ScholarPubMed
Witzig, TE, Flinn, IW, Gordon, LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262–9.CrossRefGoogle ScholarPubMed
Kaminski, MS, Tuck, M, Estes, J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441–9.CrossRefGoogle ScholarPubMed
Green, DJ, Pagel, JM, Pantelias, A, et al. Pretargeted radioimmunotherapy for B-cell lymphomas. Clin Cancer Res 2007;13(18 Pt 2):5598s–603s.CrossRefGoogle ScholarPubMed
Sweetenham, JW, Dicke, K, Arcaroli, J, et al. Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin(R)) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. ASH Annual Meeting Abstracts 2004;104:2633.Google Scholar
Press, OW, Unger, JM, Braziel, RM, et al. Southwest Oncology Group. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143–9.CrossRefGoogle Scholar
Laport, GG. The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006;12(1 Suppl 1): 59–65.CrossRefGoogle ScholarPubMed
Freedman, AS, Neuberg, D, Mauch, P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325–33.Google ScholarPubMed
Montoto, S, Canals, C, Rohatiner, AZ, et al. EBMT Lymphoma Working Party. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007;21:2324–31.CrossRefGoogle ScholarPubMed
Ladetto, M, Marco, F, Benedetti, F, et al. Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008;111:4004–13.CrossRefGoogle Scholar
Besien, K, Loberiza, FR, Bajorunaite, R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102(10):3521–9.CrossRefGoogle ScholarPubMed
Ciechanover, A, Schwarz, AL. The ubiquitin-proteasome pathway: the complexity and myriad function of proteins death. Proc Natl Acad Sci U S A 1998;95:2727–30.CrossRefGoogle ScholarPubMed
Hauser, HP, Bardroff, M, Pyrowolakis, G, et al. A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J Cell Biol 1998;141:1415–22.CrossRefGoogle ScholarPubMed
Palombella, VJ, Rando, OJ, Goldberg, AL, et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773–85.CrossRefGoogle ScholarPubMed
Peters, JM.Proteasomes: protein degradation machines of the cell. Trends Biochem Sci 1994;19:377–82.CrossRefGoogle ScholarPubMed
Coux, O, Tanaka, K, Goldberg, AL.Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801–47.CrossRefGoogle ScholarPubMed
Gray, DA, Inazawa, J, Gupta, K, et al. Elevated expression of Unph, a proto-oncogene at 3p21.3 in human lung tumors. Oncogene 1995;10:2179–83.Google ScholarPubMed
Keyomarsi, K, Conte, D, Toyofuku, W, et al. Deregulation of cyclin E in breast cancer. Oncogene 1995;11:941–50.Google ScholarPubMed
Masdehors, P, Merle-Beral, H, Maloum, K, et al. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-cell lymphocytes. Blood 2000;96:269–74.Google Scholar
Jeremias, I, Kupatt, C, Bauman, B.Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998;91:4624–31.Google ScholarPubMed
Blagosklonny, MV, Wu, GS, Omura, S, et al. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 1996;227:564–9.CrossRefGoogle ScholarPubMed
Pagano, M, Tam, SW, Theodoras, AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682–5.CrossRefGoogle ScholarPubMed
Drexler, HC.Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 2002;99:16 220–5.Google Scholar
Lops, UG, Erhardt, P, Yao, R, et al. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997;272:12 893–6.CrossRefGoogle Scholar
Voorhees, PM, Dees, CE, O'Neil, B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9:6316–25.Google ScholarPubMed
Pham, LV, Tamayo, AT, Yoshimura, LC, et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003;171:88–95.CrossRefGoogle ScholarPubMed
Hernandez-Ilizaliturri, FJ, Kotowski, A, Czuczman, MS.PS341 inhibits cell proliferation, induces apoptosis of and enhances the biological effects of rituximab on non-Hodgkin's lymphoma (NHL) cell lines and lymphoma xenografts. Blood 2003;102:3359a.Google Scholar
O' Connor, O, Srinivasan, S, Hernandez, F, et al. Oblimersen (Bcl-2 antisense) enhances the antitumor activity of bortezomib (Bor) in multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) preclinical models. Blood 2003;102:628a.Google Scholar
Ma, MH, Yang, HH, Parker, K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136–44.Google ScholarPubMed
Cusack, JC, Liu, R, Houston, M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-B inhibition. Cancer Res 2001;61:3535–40.Google Scholar
Goy, A, Younes, A, McLaughlin, P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667–75.CrossRefGoogle ScholarPubMed
O'Connor, O, Wright, J, Moskowitz, C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676–84.CrossRefGoogle ScholarPubMed
Tse, C, Shoemaker, AR, Adickes, J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421–8.CrossRefGoogle ScholarPubMed
Konopleva, M, Watt, J, Contractor, R, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15–070 (obatoclax). Cancer Res 2008;68:3413–20.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×